Evidence map›Paper›PMID 30246251›Full record

ReviewThe Journal of pathology2019

Bone morphogenetic protein receptor signal transduction in human disease.

Maria Catalina Gomez-Puerto, Prasanna Vasudevan Iyengar, Amaya García de Vinuesa, Peter Ten Dijke, Gonzalo Sanchez-Duffhues

Open access · hybridAbstract readReview
In one paragraph

Review in The Journal of pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 232 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Molecular Biology: Navigating the Landscape.Current issues in molecular biology · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. BMP2-induced Adam12International journal of biological sciences · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Maria Catalina Gomez-PuertoDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-5362-9780
Prasanna Vasudevan IyengarDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-6495-137X
Amaya García de VinuesaDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
Peter Ten DijkeDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
Gonzalo Sanchez-DuffhuesDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-3205-0710
Leiden University Medical Center · NL

Funding

CVON-PHAEDRA CVON2012-08CVON-RECONNECT CVON2014-11
6 · The paper itself

Abstract

Bone morphogenetic proteins (BMPs) are secreted cytokines that were initially discovered on the basis of their ability to induce bone. Several decades of research have now established that these proteins function in a large variety of physiopathological processes. There are about 15 BMP family members, which signal via three transmembrane type II receptors and four transmembrane type I receptors. Mechanistically, BMP binding leads to phosphorylation of the type I receptor by the type II receptor. This activated heteromeric complex triggers intracellular signaling that is initiated by phosphorylation of receptor-regulated SMAD1, 5, and 8 (also termed R-SMADs). Activated R-SMADs form heteromeric complexes with SMAD4, which engage in specific transcriptional responses. There is convergence along the signaling pathway and, besides the canonical SMAD pathway, BMP-receptor activation can also induce non-SMAD signaling. Each step in the pathway is fine-tuned by positive and negative regulation and crosstalk with other signaling pathways. For example, ligand bioavailability for the receptor can be regulated by ligand-binding proteins that sequester the ligand from interacting with receptors. Accessory co-receptors, also known as BMP type III receptors, lack intrinsic enzymatic activity but enhance BMP signaling by presenting ligands to receptors. In this review, we discuss the role of BMP receptor signaling and how corruption of this pathway contributes to cardiovascular and musculoskeletal diseases and cancer. We describe pharmacological tools to interrogate the function of BMP receptor signaling in specific biological processes and focus on how these agents can be used as drugs to inhibit or activate the function of the receptor, thereby normalizing dysregulated BMP signaling. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Indexed as

Signal TransductionAnimalsBone Morphogenetic Protein ReceptorsBone Morphogenetic ProteinsCardiovascular DiseasesHumansLigandsMusculoskeletal DiseasesNeoplasmsPhosphorylationSmad Proteins, Receptor-RegulatedBone Morphogenetic Protein ReceptorsBone Morphogenetic ProteinsLigandsSmad Proteins, Receptor-Regulatedacromesomelic dysplasiaactivinBMPbonebrachydactylycancercardiovascularfibrodysplasia ossificans progressivahematopoiesishemorrhagic telangiectasiaheterotopic ossificationjuvenile polyposis syndromepulmonary arterial hypertensionTGF-β

Identifiers

PMID30246251
PMCPMC6587955
OpenAlexW2892392763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.